Key result
Bleeding risk in atrial fibrillation represents a modifiable target rather than an unavoidable treatment consequence.
Key points are not available for this paper at this time.
Answers are grounded in this paper and cite their sources.
Jacqueline Bosch, PhD, MSc, BSc OT (Reg), Carmen Ka Man Cheung, MBChB, FHKCP, FHKAM, John Eikelboom, MBBS, MSc, FRACP; Bleeding in Atrial Fibrillation: Una
No takes yet. Share an insight, caveat, or question.
Bosch et al. (2025) studied this question. Bleeding risk in atrial fibrillation is discussed as a potentially modifiable clinical target rather than an unavoidable consequence of treatment.
Synapse has enriched 10 related papers. Consider them for comparative context: